KRAS and neoplasm: Indeed, these Mut+ peptides contain previously reported immunogenic tumor neoantigens including KRAS(G12D) (GADGVGKSA)/C*0802 (ref. 29), FLT3(D835Y) (YIMSDSNYV)/A*0201 (ref. 42) and EGFR(T790M) (IMQLMPFGC)/A*0201 (ref. 43) (Fig. 6b,c).